Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Hypoaldosteronism | Research

Aldosterone signaling defect in young infants: single-center report and review

Authors: Melati Wijaya, Huamei Ma, Jun Zhang, Minlian Du, Yanhong Li, Qiuli Chen, Song Guo

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Aldosterone (Ald) is a crucial factor in maintaining electrolyte and water homeostasis. Defect in either its synthesis or function causes salt wasting (SW) manifestation. This disease group is rare, while most reported cases are sporadic. This study aimed to obtain an overview of the etiology and clinical picture of patients with the above condition and report our rare cases.

Methods

A combination of retrospective review and case studies was conducted at the Pediatric Endocrine unit of The First Affiliated Hospital Sun Yat Sen University from September 1989 to June 2020.

Results

A total of 187 patients with SW were enrolled, of which 90.4% (n = 169) were diagnosed with congenital adrenal hyperplasia (CAH). SW type 21-hydroxylase deficiency accounted for 98.8% (n = 167) of CAH diagnosis, while 1.2% (n = 2) was of lipoid CAH. Non-CAH comprised 9.6% (n = 18) of the total patients whose etiologies included SF-1 gene mutation (n = 1), X-linked adrenal hypoplasia congenita (n = 9), aldosterone synthase deficiency (ASD, n = 4), and pseudo-hypoaldosteronism type 1 (PHA1, n = 1). Etiologies were not identified in three patients. All of patients with ASD and PHA1 exhibited SW syndrome in their early neonatal period. DNA sequencing showed mutations of CYP11B2 for P1-P4 and NR3C2 for P5. P1 and P2 were sibling brothers affected by compound heterozygous mutations of c.1121G > A (p.R374Q) and c.1486delC p.(L496fs); likewise, P4 was identified with compound heterozygous mutations of c.1200 + 1G > A and c.240–1 G > T; meanwhile P3 demonstrated c.1303G > A p.(G435S) homozygous mutation in CYP11B2 gene. Lastly, P5 showed c.1768 C > T p.(R590*) heterozygous mutation in the NR3C2 gene.

Conclusion

Etiology of infant with aldosterone defect was mostly congenital. Renal and adrenal imaging are recommended to exclude renal causes. If clinical picture is suggestive, normal plasma Ald in early infancy cannot rule out aldosterone insufficiency.
Literature
13.
15.
go back to reference Kuribayashi I, Kuge H, Santa RJ, Mutlaq AZ, Yamasaki N, Furuno T, et al. A missense mutation (GGC[<sup>435</sup>Gly]→AGC [Ser]) in exon 8 of the CYP11B2 gene inherited in Japanese patients with congenital Hypoaldosteronism. Hormone Res Paediatr. 2003;60(5):255–60. https://doi.org/10.1159/000074041.CrossRef Kuribayashi I, Kuge H, Santa RJ, Mutlaq AZ, Yamasaki N, Furuno T, et al. A missense mutation (GGC[<sup>435</sup>Gly]→AGC [Ser]) in exon 8 of the CYP11B2 gene inherited in Japanese patients with congenital Hypoaldosteronism. Hormone Res Paediatr. 2003;60(5):255–60. https://​doi.​org/​10.​1159/​000074041.CrossRef
Metadata
Title
Aldosterone signaling defect in young infants: single-center report and review
Authors
Melati Wijaya
Huamei Ma
Jun Zhang
Minlian Du
Yanhong Li
Qiuli Chen
Song Guo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00811-9

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine